Beta 1 integrin predicts survival in breast cancer: a clinicopathological and immunohistochemical study by Santos, Petra dos et al.
  Universidade de São Paulo
 
2012-08-16
 
Beta 1 integrin predicts survival in breast
cancer: a clinicopathological and
immunohistochemical study
 
 
DIAGNOSTIC PATHOLOGY, LONDON, v. 7, AUG 16, 2012
http://www.producao.usp.br/handle/BDPI/34857
 
Downloaded from: Biblioteca Digital da Produção Intelectual - BDPI, Universidade de São Paulo
Biblioteca Digital da Produção Intelectual - BDPI
Departamento de Patologia e Medicina Legal - FMRP/RPM Artigos e Materiais de Revistas Científicas - FMRP/RPM
RESEARCH Open Access
Beta 1 integrin predicts survival in breast cancer:
a clinicopathological and immunohistochemical
study
Petra Barros dos Santos1*, Juliana S Zanetti2, Alfredo Ribeiro-Silva2 and Eduardo IC Beltrão1,3
Abstract
Background: The main focus of several studies concerned with cancer progression and metastasis is to analyze the
mechanisms that allow cancer cells to interact and quickly adapt with their environment. Integrins, a family of
transmembrane glycoproteins, play a major role in invasive and metastatic processes. Integrins are involved in cell
adhesion in both cell-extracellular matrix and cell-cell interactions, and particularly, β1 integrin is involved in
proliferation and differentiation of cells in the development of epithelial tissues. This work aimed to investigate the
putative role of β1 integrin expression on survival and metastasis in patients with breast invasive ductal carcinoma
(IDC). In addition, we compared the expression of β1 integrin in patients with ductal carcinoma in situ (DCIS).
Methods: Through tissue microarray (TMA) slides containing 225 samples of IDC and 67 samples of DCIS, β1
integrin expression was related with several immunohistochemical markers and clinicopathologic features of
prognostic significance.
Results: β1 integrin was overexpressed in 32.8% of IDC. In IDC, β1 integrin was related with HER-2 (p = 0.019) and
VEGF (p = 0.011) expression and it had a significant relationship with metastasis and death (p = 0.001 and p= 0.05,
respectively). Kaplan-Meier survival analysis showed that the overexpression of this protein is very significant
(p = 0.002) in specific survival (number of months between diagnosis and death caused by the disease). There were
no correlation between IDC and DCIS (p = 0.559) regarding β1 integrin expression.
Conclusions: Considering that the expression of β1 integrin in breast cancer remains controversial, specially its
relation with survival of patients, our findings provide further evidence that β1 integrin can be a marker of poor
prognosis in breast cancer.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/6652215267393871
Keywords: β1 integrin, Tissue microarray, Immunohistochemistry, Prognosis
Background
Integrins are a family of transmembrane receptors.
They are heterodimers composed by two subunits, α
and β, which are non-covalently linked and depend of
divalent cations [1]. A total of 18α and 8β subunits
have been identified. These subunits combine to form
24 distinct heterodimers, however splice variants have
been identified for some subunits and the number can
reach at least 100 types [2,3]. These molecules can
mediate intra and extracellular signals involved in the
organization of cells, tissues and organs during deve-
lopment. Moreover they can directly or indirectly in-
fluence on many aspects of cell behavior, such adhesion,
migration and proliferation. They also play a significant
role in signal transduction events, such as gene expression
and regulation of cell apoptosis [4,5].
Invasive breast carcinoma is associated with a high
mortality rate due to invasion to the lymph nodes, adja-
cent tissues and also due to metastasis. Invasive ductal
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carcinoma (IDC) is the most common histological type,
accounting for approximately 40–75% of all cases. IDC
has a relatively poor prognosis with 35–50% 10-year sur-
vival rate [6,7]. Traditionally, as also verified in several
other solid tumors, peritumoral lymphatic and blood in-
vasion are the main factor related to the presence of
lymph node metastasis and, in breast cancer, they are
more closely related to tumor size and histological grade
and it is known that integrins are closely related to these
processes [8,9].
β1 integrin is the mainly expressed integrin in normal
cells and in tumor-associated cells, in which they control
various developmental processes including angiogenesis,
tumor progression and metastasis [10]. These integrins
typically mediate adhesion of epithelial cells to the base-
ment membrane. They may also contribute to cell sur-
vival of tumor cells by interacting with others molecules.
β1 integrin usually activate cytokine receptors or growth
factors receptors (FGRs) and as a result, the tumor
growth and invasion probably depends on the crosstalk
with certain integrins, FGRs and/or oncogenes in tumor
cells and tumor-associated cells [11]. Based on these
observations, β1 integrin has become a target of interest
for immunotherapy in several types of cancers, including
breast cancer [12]. In recent years, several β1 integrins
antagonists have been studied [13,14].
Over the last years, the study of ductal carcinoma in
situ (DCIS) associated with invasive carcinoma has
helped to understand the mechanisms involved in dis-
ease progression from DCIS to IDC [15]. Many studies
have been reported conflicting results about the role of
integrins in cancer cells and also in the patients’ survival,
and how these integrins may contribute to metastasis
[16,17]. We aimed to evaluate the β1 integrin expression
in IDC and its relationship with several biomarkers and
clinicopathologic features of prognostic significance. In
addition, we compared the pattern of β1 integrin expres-
sion in IDC and DCIS.
Methods
Casuistic
This study was approved by the local Research Ethics
Committee. Formalin-fixed, paraffin-embedded samples
of IDC and DCIS from 300 and 100 patients, respect-
ively, diagnosed from 1994 to 2010, were randomly
chosen from the archives of Department of Pathology-
Ribeirão Preto Medical School, São Paulo University.
The clinical data of these patients were retrieved from
medical files, and included age, menopausal status,
tumor size, metastasis to regional lymph nodes, recur-
rence, distant metastasis and death. Disease-specific sur-
vival, metastasis-free survival and disease-free survival
were defined by Zanetti and colleagues [18].
For DCIS patients the following information was
retrieved from clinical and pathological records: age,
menstrual status, hormone receptors status (ER and PR),
nuclear grade (low, intermediary and high), tumor size
and if the tumor was multifocal or not.
Tissue microarray (TMA)
All hematoxylin and eosin stained slides were reviewed by
an experienced breast pathologist (ARS). Three tissue
microarrays (TMA) paraffin blocks were constructed from
the IDC cases (100 cases per TMA) and five TMA paraffin
blocks were constructed containing 24 DCIS cases per
TMA. For the construction of the IDC and DCIS TMAs,
core biopsies of 1-mm diameter were punched from the
selected regions of each donor paraffin blocks and arrayed
into the TMA receptor block. One section of each was
stained with hematoxylin and eosin to confirm the pres-
ence of the tumor by light microscopy. The three IDC’s
TMAs contained a total of 300 samples; however, 75 cases
had to be excluded because of insufficient amount of
tumor in the core. In that way, the study was performed
in the 225 remaining cases that had high quality tissue
spot that could be read for β1 integrin and the others mar-
kers. DCIS’s TMAs contained a total of 100 samples but
only 67 had enough tumor tissue at the core, which were
included in the analysis.
Immunohistochemistry
Sections (3 μm) were obtained from the TMAs paraffin
blocks and immunohistochemical reactions were per-
formed with the Mach 4 Universal Polymer Detection
kit (Biocare Medical, CA, USA) following protocols that
were described elsewhere [18,19]. β1 integrin was
detected using clone 4B7R (1:100) and VEGF with clone
A-20 (1:100), both from Santa Cruz, Palo Alto, USA.
The other antibodies are from Novocastra, Newcastle
upon Tyne, UK: p53 (1:50, clone DO-7), ER (1:100, clone
6 F11), PR (1:100, clone 16), HER-2 (1:100, clone CB11)
and Ki67 (1:100, clone MM1). Normal liver samples
were used as positive control for β1 integrin. IDC cases
previously known to be positive for Ki67, ER, PR, p53,
HER-2 were used as positive controls for each reaction.
Negative controls were prepared omitting the primary
antibody.
Immunohistochemistry evaluation
β1 integrin cut-off was based according to Yao and col-
leagues [20] in which sample was scored based on the
intensity of signal (0, 1+, 2+ 3+) and the percentage of
positive cells (0 ≤ 10%, 1 = 10–25%, 2 = 25–50%, 3 ≥ 50%).
For statistical analysis we used the same method estab-
lished by Petricevic and colleagues [21] where the results
were presented as a positive (strong positive staining 3+
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and moderately positive staining 2+) or a negative (weak
positive 1+ and negative staining 0) for tumor cells.
HER-2 was evaluated according to the ASCO/CAP
HER2 guideline [22] and cases as 2+ were submitted to
chromogenic in situ hybridization (CISH) [23]. Only
HER-2 2+ cases in immunohistochemistry amplified on
CISH were considered positive for statistical purposes.
VEGF immunoscoring, according to Giatromanolaki and
colleagues [24], was divided into two groups regarding the
extent of positive staining: low/medium reactivity (0–69%
positive cells) and high reactivity (70-100% positive cells).
For ER and PR we follow the recommendations of the
ASCO/CAP ER/PR guidelines (2010) [25]. Ki67 was
evaluated following Fountzilas and collegues [26] and
cases were considered highly proliferative when more
than 14% of neoplastic cells nuclei were positive. p53
were considered positive if more than 5% of the neoplas-
tic cells showed nuclear staining [27].
Chromogenic in situ hybridization (CISH)
Sections (3 μm) were cut from paraffin blocks of HER-2
cases with 2+ immunohistochemistry positivity. ZytoDot
2C SPEC HER2/CEN 17 probe kit (Zytovision, Bremer-
haven, Germany) was used for the detection of the
human HER-2 gene and alpha-satellites of chromosome
17 (CEN 17). Procedures were according to manufac-
turer’s instructions where two green (HER-2) and two
red (CEN 17) signals were expected in a normal inter-
phase nucleus. HER-2 was considered amplified when
the HER-2/CEN 17 ratio was ≥ 2 for 60 cells [28]. Only
2+ biopsies by immunohistochemistry in which HER-2
was also amplified on CISH were considered positive.
Statistical methods
Data analysis was performed with SPSS v19.0 (SPSS Inc.,
Woking, UK) with p <0.05 for significance. Relation be-
tween β1 integrin, VEGF, HER-2 and the routine labora-
tory markers and clinicopathologic features were analyzed
by Fisher exact test (two variables) or Chi-square tests
(three or more variables), and all tests were two-tailed.
Univariable survival analysis (disease-specific survival,
disease-free survival and metastasis-free survival) were
made with the log rank test and all results were displayed
in Kaplan–Meier. A Cox Proportional Hazards Model was
performed to observe the independent prognostic value of
immunoexpression of β1 integrin.
Results
Relationship between the expression of β1 integrin with
clinicopathological features and biological markers
IDC cases with less than 50% of representative tumor
area by hematoxilin eosin staining were excluded. Two
hundred twenty five cases of IDC were then analyzed.
The average age of patients included in this study was
55 years old (range 25–85 years).
There was no significant relation between the expres-
sion of β1 integrin with biomarkers such ER and PR.
These results are shown in Table 1. β1 integrin positive
tumors did not correlate with tumor size, pathologic
stage, age, menstrual status, lymph node status and
tumor grade but presented a close relation with death
and metastasis (p = 0.001 and p = 0.05, respectively) as
well as with HER-2 (p = 0.019) and VEGF (p = 0.011).
Survival analysis
Chi-square test for β1 integrin and correlation for death
and metastasis showed that 35 patients died and that 34
out of these had β1 integrin superexpression and that 36
patients developed metastasis and that 26 out of them
had β1 integrin superexpression. The Kaplan-Meier test
was used to estimate the survival time of patients that
expressed or not β1 integrin during the research time
(maximum 164 months). Our results indicate that the
expression of β1 integrin has an impact in disease-
specific survival (number of months from diagnosis to
the time of death due to breast cancer) with p = 0.002
(Figure 1). For metastasis-free survival (Figure 2) and
disease-free survival (Figure 3) no significant relation
was observed (p = 0.061 and p = 0,252, respectively).
A Cox Proportional Hazards Model was performed to
observe the independent prognostic value of β1 integrin
expression with several prognostic factors such meno-
pausal status, clinical stage, Bloom-Richardson, recur-
rence, but no correlation was found; data not shown.
IDC x DCIS
The expression of β1 integrin was also evaluated in 67
patients with DCIS. The average age of patients included
in this study was 51 years old (range 23–84 years).
Forty-two cases were presented as multifocal and the
architectural pattern was mostly solid, comedo and cri-
briforme, and in our casuistic, 42 cases was associated
with invasive carcinoma. Representative samples of IDC
and DCIS are shown in Figure 4. There was no signifi-
cant relation between the expression of the β1 integrin
in DCIS with clinical and pathological factors of prog-
nostic significance. Twenty-two patients were positive
for β1 integrin where 10 were pre-menopausal and 12
were post-menopausal. Nineteen presented high nuclear
grade and only three patients had low nuclear grade.
The relation between the expression of biomarkers,
such as ER and PR, and β1 integrin in IDC and DCIS
were not significant (Table 2).
Discussion
According to Kononen and colleagues [29] tissue micro-
arrays (TMAs) were developed to allow high throughput
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analysis of protein expression in tumors tissues and
many authors agree that they can be used to validate
biomarkers [30-32]. Here, β1 integrin expression and its
relationship with survival of patients with IDC were ana-
lyzed in a tissue microarray.
During the last years a number of reports have linked
integrins to tumorigenicity ranging from local tumor
growth to metastasis [33] and it is well documented that
integrins contribute to migration and invasion of cancer
cells [34]. β1 integrin is the most widely expressed integ-
rin in cells and has been suggested to play a role in pre-
dicting the clinical course and prognosis of several types
of cancers [20]. However, Brakebusch and colleagues
[35] argue that it is not surprising that some studies link
tumorigenicity to β1 integrin in the form of down- or
up-regulated expression. For example, according to Guo
and colleagues [36] β1 integrin is the most abundantly
expressed integrin in Non-small-cell lung carcinoma and
Table 1 Relationship between β1 integrin expression with clinicopathologic features and classical
immunohistochemical markers in breast cancer, including VEGF
Clinicopathologic
Features and
Immunohistochemical
Markers
β1 Integrin- β1 Integrin+ P-value
n (151) (%) n (74) (%)
Age (years) <50 65 43.0 27 36.5 0.213a
>50 86 67.0 47 63.5
Menstrual Status Pre-menopausal 54 35.8 24 32.4 0.367a
Post-menopausal 97 64.2 50 67.6
Size (mm) <20 49 32.5 19 25.7 0.442b
20-50 55 36.4 33 44.6
>50 47 31.1 22 29.7
Tumoral Grade I 57 37.7 25 33.8 0.845b
II 71 47.0 37 50.0
III 23 15.2 12 16.2
Lymph node Status Negative 75 49.7 33 44.6 0.283a
Positive 76 50.3 41 55.4
Clinical Stage I 22 14.6 10 13.5 0.677b
II 72 47.7 30 40.5
III 49 32.5 30 40.5
IV 8 5.3 4 5.4
Death No 116 76.8 40 54.1 0.001a
Yes 35 23.2 34 45.9
Metastasis No 115 76.2 48 64.9 0.05a
Yes 36 23.8 26 35.1
ER Negative 48 31.8 21 28.4 0.359a
Positive 103 68.2 53 71.6
PR Negative 64 42.4 33 44.6 0.431a
Positive 87 57.6 41 55.4
p53 Negative 114 75.5 51 68.9 0.187a
Positive 37 24.5 23 31.1
Ki-67 Negative 107 70.9 54 73.0 0.435a
Positive 44 29.1 20 27.0
HER2 Negative 126 83.4 52 70.3 0.019a
Positive 25 16.6 22 29.7
VEGF Negative 114 75.5 66 89.2 0.011a
Positive 37 24.5 8 10.8
aFisher’s exact test; bChi-square test.
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other authors [37] founded that its expression has been
associated with lymph node metastasis in the same type
of cancer. Although Kren and colleagues [38] noted that
the low expression of β1 integrin promoted tumor cells
dissemination in a mouse model of pancreatic β cell
carcinogenesis.
In regard to breast cancer, some studies have reported
that decreased β1 integrin expression was associated
Figure 1 Univariate analysis: the prognostic impact of β1 integrin status on disease-specific survival of breast cancer patients
(p = 0.002). (Using Kaplan-Meier table followed by log-rank test).
Figure 2 Kaplan-Meier survival curves: comparison of the expression of β1 integrin (green solid line) to negativity (blue solid line) in
metastasis-free survival (MFS) demonstrating the non-significant (p = 0.061) but clearly divergent curves. (Using Kaplan-Meier table
followed by log-rank test).
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Figure 3 Lack of significant difference (p= 0.252) in the curves for presence (green solid line) or absence (blue solid line) of expression
for β1 subunit in disease free-survival (DFS). (Using Kaplan-Meier table followed by log-rank test.).
Figure 4 Immunohistochemistry for β1 integrin in Invasive and In situ Breast Carcinoma. DCIS: (A) negative (100×) and (B) positive (200×);
IDC: (C) positive (200x) and (D) detail with 400x of the circled area. β1 integrin can be found both in cytoplasm and plasma membrane. (SP
method, high power microscopic view).
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with characteristics of more aggressive disease [39,40],
while others observed that the high expression of β1 in-
tegrin is associated with decrease survival [20]. Berry
and colleagues [41] and Petricevic and co-workers [21]
verified no significant correlation with β1 integrin ex-
pression and survival of patients with breast carcinoma.
Then, it is possible to realize that there are controversies
in the studies concerning the expression of this protein
as well as its relation with survival rate in patients with
breast cancer.
We choose the same score used by Yao and colleagues
[20] based on the level of signal and percentage of tumor
cells expressing the signal. Here, we provide evidences that
β1 integrin high expression (2+ and 3+) can be predictive
of response and has impact on specific-free survival in
patients with breast cancer. Ours findings did not relate
β1 integrin with metastasis free survival. Some authors
suggested that β1 integrin is important but not essential
for metastasis [35]. All these findings are in accordance
with previous reports in different types of cancer [42-44],
including previous studies that showed that β1 integrin in-
hibition induces apoptosis in breast cancer cells [45].
The basement membranes are reservoirs for growth
factors [46] and it is well known that specific integrins
can activate specific FGRs [11]. For example, Hayashida
and colleagues [47] founded that β1 integrin are depend-
ently linked with TGF-β1, and that knocking β1 integrin
down enhances the cell collagen production trough
TGF-β1. Nowadays, it is well known that the interaction
between FGRs and integrins can regulate cell survival
and proliferation and supporting tumor growth [48,49].
Some studies linked β1 integrin with members of the
FGR family including VEGF [50]. This can promote
angiogenesis through up-regulation and/or activation of
integrins [51]. Other study demonstrated that VEGF ac-
tivity is dependent on β1 integrin function. In this study
the authors founded that the knockout of β1 integrin in
embryonic stem cells, neither the proliferation of the
endothelial cells nor sprouting of blood vessels occurred,
suggesting that VEGF had no effect in β1-null embryoid
bodies [52]. More interestingly Lee and colleagues [51]
with in vitro studies, with human brain microvascular
endothelial cells, showed that blocking β1 integrin, all
processes of angiogenesis was inhibited (adhesion, mi-
gration, and capillary morphogenesis) and they also sug-
gested that the α6β1 integrin is closely related to the
metastasis of breast cancer cells to the brain.
Studies have demonstrated that some oncogenes re-
quire specific integrins for tumorigenicity. Integrins are
not oncogenic molecules, but some of them can cooper-
ate with oncogene to initiate growth, invasion and pro-
gression of the cancer [11]. In a transgenic mouse model
of human breast cancer some authors founded that β1
integrin mediates the initiation of mammary tumorigen-
esis that is driven by the polyoma middle T oncoprotein
[53].
Recent data suggest a relationship between HER-2 and
β1 integrin. Shimizu and colleagues [54], in a study with
breast cancer cell line, suggested that the α6β1 integrin
inhibits HER-2 signals by proteolytic cleavage of the
cytoplasmic domain of HER-2 and this could also con-
tribute to the regulation of tumor growth. Other authors
[55] demonstrated that even under adverse conditions
such as hypoxia and chemotherapeutic treatments there
is a strong regulation between HER-2 signaling stimulat-
ing the expression of the integrin α5 and β1 which pro-
motes tumor cell survival.
In the present study, we found a relationship between
low expression of β1 integrin and negativity for HER-2
demonstrating some evidence that this subgroup of
patients might have a less aggressive phenotype. Besides,
we showed that patients who had high β1 integrin ex-
pression showed the poor prognostic.
Angiogenesis is induced by VEGF through its inter-
action with receptors expressed primarily on the vascular
endothelial cell membrane [18] and is well known that
tumors depend largely on effective angiogenesis [35]. The
amplification of the proto-oncogene HER-2 is observed in
approximately 15–30% of all breast cancer samples and
has been correlated with a shorter survival [23,56]. An im-
portant aspect of the involvement of β1 integrin in angio-
genesis and tumorigenicity is the potential implication for
tumor treatment [57]. This study shows that β1 integrin
expression on tumor cells actually promote tumor pro-
gression and acts as a tumor enhancer. In addition, our
results indicate that both expression of the β1 integrin
and its association with HER-2 and VEGF may be useful
in targeted therapies for patients with breast cancer.
One of the main focuses concerning breast cancer has
been the identification of the molecular alterations asso-
ciated with the different stages of the progression dis-
ease. According to Bombonati and Sgroi [7] the current
model of human breast cancer progression proposes a
Table 2 Frequency of β1 integrin (β1), Progesterone
Receptor (PR) and Estrogen Receptor (ER) expression in
breast carcinomas
Markers Group P-
valueIDC DCIS
n (%) n (%)
β1 Negative 151 (67,1) 45 (67,2) 1.000a
Positive 74 (32,9) 22 (32,8)
PR Negative 87 (38,7) 20 (29,9) 0.198a
Positive 138 (61,3) 47 (70,1)
ER Negative 76 (33,8) 17 (25,4) 0.233a
Positive 149 (66,2) 50 (74,6)
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linear multi-step process which initiates as flat epithelial
atypia, progresses to atypical ductal hyperplasia, evolves
into DCIS and culminates in the potentially lethal stage
of IDC. In our study we do not found association with
the expression of β1 integrin in IDC and DCIS. 67,1% of
the IDC cases were negative for β1 integrin and 67,2%
were negative in DCIS cases, with no significant relation
probably due to the limited number of cases.
Conclusions
Subgroups of patients with negativity for β1 integrin and
HER-2 might have a less aggressive phenotype. Taken to-
gether with the differential expression of VEGF these
findings may be useful in targeted therapies for patients
with breast cancer. Although there was no association
between β1 integrin expression in IDC and DCIS the re-
lationship in these types of cancer needs to be better
understood, and further studies are needed to clarify the
molecular basis involved in this process.
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